CGBIO Inc., a Korea's Regenerative Medicine company, has announced a successful partnership agreement with NDR Medical Technology, a Singapore-based company, to introduce an Automated Needle Targeting (ANT)-X system that combines Artificial Intelligence (AI) and medical image processing to assist surgeons during minimally invasive surgery and to collaborate in clinical studies.

CGBIO expects this partnership to be of great help to promoting the mutual medical technology collaboration between Singapore and Korea as well as expanding its globalization strategy of local medical technology in the years to come.

Under the partnership with NDR, CGBIO will carry out clinical studies with local prominent doctors as part of efforts to expand the ANT system in a wide range of interventional procedures that need percutaneous need placement in urology, orthopedics, neurosurgery, etc., coupled with a study to finalize the launching ANT-C, a CT-guided robot.

Graduates from Nanyang Technology founded NDR Medical Technology in 2015 and developed the world's first AI-empowered interventional robot systems.

For global expansion, NDR has obtained CE certification for ANT-X and completed clinical studies in Japan and Southeast Asian countries.